ATG-031 

ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)^[1][2][3].

Human

CD24

ATG-031 可与 CD24 阳性的肿瘤细胞强效结合，但与 HEK293 细胞或 hRBC 无结合^[1]。
ATG-031 可阻断 CD24 与 Siglec-10 之间的相互作用，并诱导强效的巨噬细胞依赖性肿瘤细胞吞噬作用^[1]。
ATG-031 可诱导针对 HT-29 肿瘤细胞的强效抗体依赖性细胞毒性，其 EC₅₀ 为 0.27 nM^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ATG-031 (1-3 mg/kg，静脉注射，每两周一次) 在 MC38-hCD24 小鼠模型中显著抑制肿瘤生长并诱导肿瘤消退^[1]。
ATG-031 作为单一药物在 MC38、CT26 和 4T1 等同基因模型中表现出强大的体内抗肿瘤活性^[3]。
ATG-031 在体内与化疗和检查点抑制剂表现出协同作用^[3]。
ATG-031 (3 mg/kg，静脉注射，两次给药) 在携带 MC38-hCD24 肿瘤的 C57BL/6 小鼠中，在细胞和单细胞转录组水平上显著增强 T 细胞相关免疫反应^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

100133941  [NCBI]

P25063-1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.305 kDa

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Loaded CD24 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78913) on AHC2 biosensor, can bind ATG-031 with an affinity constant of 8.121E-09 M as determined in BLI assay.
• 
  Immobilized Biotinylated Human CD24, at 5 μg/mL (100 μL/well, HY-P78913) on streptavidin precoated (0.5 μg/well) plate, can bind Anti-CD24 Mab (HY-P99176). The ED50 for this effect is 2.899 ng/mL.

• [1]. Peng Chen, et al., (2022). ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal. Journal for ImmunoTherapy of Cancer 2022.

  [2]. Peng Chen, et al., Abstract 6641: ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME. Cancer Res 1 April 2023; 83 (7_Supplement): 6641.

  [3]. Chen P, et al., 1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignanciesJournal for ImmunoTherapy of Cancer 2023;11